Abstract
Alzheimer's Disease (AD) is an invalidating neurodegenerative disorders frequently affecting the aging population. In view of the increase of elderlies, not only in western countries, the related growing societal problems urge for identifying clinical biomarkers in view of potential treatments interfering or blocking the disease course. Among the plenty of anatomo-functional in vivo imaging techniques to inspect brain circuits and physiology, the Magnetic Resonance Imaging (MRI), the functional MRI (fMRI), the Electroencephalography (EEG) and Magnetoencephalography (MEG), have been extensively used for the study of AD, with different achievements and limitations. Eventually, the methodologies summoned by brain connectomics further strengthen the expectations in this field, as shown by recent results obtained with [18F]2-fluoro-2-deoxyglucose 18FDG-PET and fMRI in the prediction of the AD in early stages. However, the inherent complexity of the pathophysiology of the AD suggests that only integrative approaches combining different techniques and methodologies of brain scanning could produce significant breakthroughs in the study of AD. This review proposes a formal framework able to combine brain connectomic data from multimodal acquisitions by means of different in vivo neuroimaging techniques, briefly reporting their different advantages and drawbacks. Indeed, a specialized complex multiplex network, where nodes interact in layers linking the same pair of nodes and each layer reflects a distinct type of brain acquisition, can model the plurality of connectomes recommended in this framework.
Keywords: Alzheimer’s Disease, fMRI, MRI, PET, EEG, multiplex networks, brain connectomes, high-resolution multimodal scanner.
Current Alzheimer Research
Title:Integration of 18FDG-PET Metabolic and Functional Connectomes in the Early Diagnosis and Prognosis of the Alzheimer's Disease
Volume: 13 Issue: 5
Author(s): Antonio Giuliano Zippo and Isabella Castiglioni
Affiliation:
Keywords: Alzheimer’s Disease, fMRI, MRI, PET, EEG, multiplex networks, brain connectomes, high-resolution multimodal scanner.
Abstract: Alzheimer's Disease (AD) is an invalidating neurodegenerative disorders frequently affecting the aging population. In view of the increase of elderlies, not only in western countries, the related growing societal problems urge for identifying clinical biomarkers in view of potential treatments interfering or blocking the disease course. Among the plenty of anatomo-functional in vivo imaging techniques to inspect brain circuits and physiology, the Magnetic Resonance Imaging (MRI), the functional MRI (fMRI), the Electroencephalography (EEG) and Magnetoencephalography (MEG), have been extensively used for the study of AD, with different achievements and limitations. Eventually, the methodologies summoned by brain connectomics further strengthen the expectations in this field, as shown by recent results obtained with [18F]2-fluoro-2-deoxyglucose 18FDG-PET and fMRI in the prediction of the AD in early stages. However, the inherent complexity of the pathophysiology of the AD suggests that only integrative approaches combining different techniques and methodologies of brain scanning could produce significant breakthroughs in the study of AD. This review proposes a formal framework able to combine brain connectomic data from multimodal acquisitions by means of different in vivo neuroimaging techniques, briefly reporting their different advantages and drawbacks. Indeed, a specialized complex multiplex network, where nodes interact in layers linking the same pair of nodes and each layer reflects a distinct type of brain acquisition, can model the plurality of connectomes recommended in this framework.
Export Options
About this article
Cite this article as:
Zippo Giuliano Antonio and Castiglioni Isabella, Integration of 18FDG-PET Metabolic and Functional Connectomes in the Early Diagnosis and Prognosis of the Alzheimer's Disease, Current Alzheimer Research 2016; 13 (5) . https://dx.doi.org/10.2174/1567205013666151116142451
DOI https://dx.doi.org/10.2174/1567205013666151116142451 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
Early nutritional intervention and physical activity in the prevention of Alzheimer's disease and other dementias
The aim is to broaden the knowledge about the impact of the consumption of food ingredients, diet ingredients, methods of processing of food raw materials as well as the impact of composing of diets on the possibility of preventing Alzheimer's disease and other types of dementia at each stage of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Homocysteine, Intracellular Signaling and Thrombotic Disorders
Current Medicinal Chemistry The Dawn of Mitophagy: What Do We Know by Now?
Current Neuropharmacology From Surface to Nuclear Receptors: The Endocannabinoid Family Extends its Assets
Current Medicinal Chemistry Recent Advances on α-Synuclein Cell Biology: Functions and Dysfunctions
Current Molecular Medicine The Applications of Pharmacogenomics to Neurological Disorders
Current Molecular Medicine Editorial (Hot Topic: Glial Proteins and Peptides: Implications in Neuroinflammation)
Current Protein & Peptide Science Multi-Target-Directed Ligands in Alzheimer's Disease Treatment
Current Medicinal Chemistry Role of Mitochondrial Translocator Protein (18 kDa) on Mitochondrial- Related Cell Death Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Impact and Therapeutic Potential of PPARs in Alzheimers Disease
Current Neuropharmacology Recent Developments in Drug Design of NO-donor Hybrid Compounds
Mini-Reviews in Medicinal Chemistry Enantioselective Synthesis and Preliminary Pharmacological Evaluation of the Enantiomers of Unifiram (DM232), a Potent Cognition-Enhancing Agent
Medicinal Chemistry Timing is Everything
Current Neurovascular Research In Vitro Metabolism Studies of New Adenosine A Receptor Antagonists
Drug Metabolism Letters Autophagy and Mitochondria: Targets in Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets Techniques to Investigate Neuronal Mitochondrial Function and its Pharmacological Modulation
Current Drug Targets Subject Index to Volume 3
Current Drug Targets - CNS & Neurological Disorders Evolution of Specific Cognitive Subprofiles of Mild Cognitive Impairment in a Three-Year Longitudinal Study
Current Aging Science Monoamine Oxidases: The Biochemistry of the Proteins As Targets in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry Recent Medicinal Chemistry Studies against Neurodegenerative Diseases
Current Neuropharmacology The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design